EXEL - Exelixis, Inc.
| Previous Close | 19.91 |
| Open | 19.87 |
| Bid | 19.62 x 800 |
| Ask | 19.92 x 900 |
| Day's Range | 19.67 - 19.92 |
| 52 Week Range | 13.42 - 25.31 |
| Volume | 1,970,428 |
| Avg. Volume | 3,009,447 |
| Market Cap | 5.945B |
| Beta (3Y Monthly) | 1.77 |
| PE Ratio (TTM) | 9.48 |
| EPS (TTM) | 2.08 |
| Earnings Date | Jul 30, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.08 |
- Markit•6 days ago
See what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXELView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EXEL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $321 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- MoneyShow•9 days ago
Exelixis Bets on Breakthroughs in Oncology
Based in San Francisco, Exelixis (EXEL) is a drug company that is dedicated to the discovery, development and commercialization of new medicines for cancer treatment, asserts Mark Skousen, growth stock expert and editor of Five-Star Trader.
- Motley Fool•10 days ago
Top 5 Stocks in the Fight Against Cancer
These stocks are leading the way in their respective areas in battling cancer.
- Zacks•16 days ago
Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•17 days ago
Is Exelixis, Inc.'s (NASDAQ:EXEL) CEO Being Overpaid?
Michael Morrissey became the CEO of Exelixis, Inc. (NASDAQ:EXEL) in 2010. This analysis aims first to contrast CEO...
- Business Wire•18 days ago
Exelixis Announces Webcasts of Investor Conference Presentations in June 2019
̶ Presentations to be webcast on www.exelixis.com ̶
- Zacks•23 days ago
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
- Zacks•25 days ago
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
- Business Wire•last month
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
Exelixis, Inc. (EXEL) today announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics, Inc. (Iconic), a private biopharmaceutical company focused on cancer and retinal disease, to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer. This collaboration reflects Exelixis’ ongoing strategy to build a pipeline beyond its lead product, CABOMETYX, through both internal drug discovery and external business development. This agreement with Iconic is Exelixis’ second strategic collaboration focused on novel biologics, following the company’s collaboration with Invenra, Inc. announced in May 2018.
- Zacks•last month
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
- Business Wire•last month
Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019
̶ Presentations to be webcast on www.exelixis.com ̶
- Motley Fool•last month
These 3 Value Stocks Are Absurdly Cheap Right Now
You have to look hard to see value in today's pricey market, but here are three inexpensive stocks that should be on your radar today.
- Thomson Reuters StreetEvents•last month
Edited Transcript of EXEL earnings conference call or presentation 1-May-19 9:00pm GMT
Q1 2019 Exelixis Inc Earnings Call
- Business Wire•last month
Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan
Exelixis, Inc. (EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies’ collaboration agreement.
- Benzinga•last month
Jim Cramer Weighs In On Zebra Technologies, Exelixis And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Zebra Technologies Corp. (NASDAQ: ZBRA) is a fast-growing company and he is sticking by it because barcode technology is the way of the future. Cramer is not a buyer of EQM Midstream Partners LP (NYSE: EQM). Exelixis, Inc. (NASDAQ: EXEL) is a good spec, said Cramer.
- Motley Fool•last month
Where Will Gilead Sciences Spend Its Cash?
Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.
- Motley Fool•last month
Exelixis Expands Its Sales
The biotech produced solid top-line growth spurred by a new approval for Cabometyx.
- Simply Wall St.•last month
Estimating The Fair Value Of Exelixis, Inc. (NASDAQ:EXEL)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Exelixis, Inc. (NASDAQ:EXEL) from its intrinsic value? Using the most recent financial...
- Zacks•last month
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Motley Fool•last monthExelixis Inc (EXEL) Q1 2019 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Exelixis (EXEL) Beats Q1 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 12.50% and 5.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Exelixis: 1Q Earnings Snapshot
On a per-share basis, the Alameda, California-based company said it had net income of 24 cents. Earnings, adjusted for stock option expense, came to 27 cents per share. The results exceeded Wall Street ...
- Business Wire•2 months ago
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
– COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors –
